Evidence mapPaperPMID 42074063Full record

ArticleInternational journal of molecular sciences2026

Unveiling a Novel Molecular Interaction and Pro-Metastatic Signaling Cascades Driven by KRIT1.

Lucrezia Paradisi, Paolo Guazzi, Matteo Macis, Francesca Finetti, Alfonso Trezza, Raffaella De Paolo, Marta Roncetti, John F Marshall, Laura Poliseno, Federica Finetti and 1 more

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Lucrezia ParadisiDepartment of Biotechnology, Chemistry and Pharmacy, University of Siena, Via Aldo Moro 2, 53100 Siena, Italy.ORCID 0009-0004-4998-2268
Paolo GuazziHansaBioMed Life Sciences Ltd., 12618 Tallinn, Estonia.
Matteo MacisDepartment of Biotechnology, Chemistry and Pharmacy, University of Siena, Via Aldo Moro 2, 53100 Siena, Italy.ORCID 0009-0004-6862-1732
Francesca FinettiDepartment of Life Science, University of Siena, Via Aldo Moro 2, 53100 Siena, Italy.
Alfonso TrezzaDepartment of Biotechnology, Chemistry and Pharmacy, University of Siena, Via Aldo Moro 2, 53100 Siena, Italy.
Raffaella De PaoloInstitute of Clinical Physiology (IFC), Italian National Research Council (CNR), Via Moruzzi 1, 56124 Pisa, Italy.ORCID 0000-0002-9151-2866
Marta RoncettiInstitute of Clinical Physiology (IFC), Italian National Research Council (CNR), Via Moruzzi 1, 56124 Pisa, Italy.ORCID 0000-0003-0237-4359
John F MarshallBarts Cancer Institute, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK.
Laura PolisenoInstitute of Clinical Physiology (IFC), Italian National Research Council (CNR), Via Moruzzi 1, 56124 Pisa, Italy.ORCID 0000-0001-6557-955X
Federica FinettiDepartment of Biotechnology, Chemistry and Pharmacy, University of Siena, Via Aldo Moro 2, 53100 Siena, Italy.ORCID 0000-0003-1144-3360
Lorenza TrabalziniDepartment of Biotechnology, Chemistry and Pharmacy, University of Siena, Via Aldo Moro 2, 53100 Siena, Italy.ORCID 0000-0002-0850-7186

Funding

Piano per lo Sviluppo della Ricerca (PSR), F-DIP, University of Siena XXXTelethon GGP15219
6 · The paper itself

Abstract

K-Rev Interaction Trapped protein-1 (KRIT1) is a scaffold protein that forms functional protein complexes involved in physiologically important signaling networks. While it is primarily recognized for its association with Cerebral Cavernous Malformations (CCMs), KRIT1 may also play critical roles in tumor formation and the acquisition of malignant phenotypes, regulating cell adhesion, cytoskeletal dynamics, and angiogenesis. In this study, we investigated the role of KRIT1 in cancer cell migration and metastasis, with a focus on identifying novel interacting proteins and characterizing the intracellular signaling pathways activated upon its loss. By using a yeast two-hybrid screening, we identified Kinesin Family Member 1C (KIF1C), a protein involved in regulating podosome and invadopodium elongation, as a novel binding partner of KRIT1, and the interaction was confirmed in melanoma and epithelial cancer cells. In silico docking and interaction interface analyses supported the KRIT1-KIF1C interaction, providing structural insight into the binding mode as shown experimentally. We also found that SRC and focal adhesion kinase (FAK) phosphorylation, as well as Ras homolog family member A (RhoA) expression, represent additional pathways affected by the loss of KRIT1. This study confirms our earlier hypothesis that KRIT1 functions as a tumor suppressor and uncovers a compelling link between its loss and enhanced cancer aggressiveness.

Indexed as

KinesinsKRIT1 ProteinSignal TransductionCell Line, TumorCell MovementHumansMolecular Docking SimulationNeoplasm MetastasisPhosphorylationProtein BindingKinesinsKRIT1 ProteinKRIT1 protein, humancancer cell migrationcytoskeletondocking simulationKIF1CKRIT1molecular modelingtumor metastasistumor suppressor

Identifiers

PMID42074063
PMCPMC13117016

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.